United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer Inc.'s stock gained Monday after a report that activist investor Starboard Value has invested $1 billion in the drug company. Bondholders seem to like the news too.

Pfizer's bondholders cheer news of activist investor Starboard's $1 billion investment

As activist Starboard teams up with former Pfizer executives, the pharma giant's lack of focus is in the spotlight.

Pfizer CEO's Job Is at Risk. A Shot of Discipline Could Help.

Pfizer (PFE) shares have gained ground since theThe Wall Street Journal reported over the weekend that activist investor Starboard Value has taken a roughly $1 billion stake in the drug maker and is pushing for changes at the company.

Watch These Pfizer Price Levels as Stock Gains After Report of Starboard Taking Stake

Pfizer, yielding 5.6%, is an Ultra SWAN bargain with upside potential in the next year. Despite $70 billion in debt, Pfizer's A- credit rating and stable cash flow ensure long-term stability and very strong dividend safety. Pfizer's growth outlook includes a 5% long-term growth rate, with a 10% to 11% long-term return potential.

Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential

GlaxoSmithKline

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.

GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up

BioNTech SE

CureVac B.V

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

AstraZeneca

Bayer AG

Eli Lilly

Sanofi

Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

Pfizer's stock has likely bottomed and shows strong technical and fundamental indicators, including a "Golden Cross" and robust cost reduction plans. The company's promising pipeline, including weight-loss treatments and AI-driven drug discovery, offers significant long-term upside potential. The Seagen acquisition enhances Pfizer's cancer treatment portfolio, positioning it well in a high-demand sector.

Pfizer: A Strong Product Pipeline Could Lead To Significant Upside

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Why Pfizer Will Find It Hard to Appease Its Activist Investor

Starboard Value has taken a $1 billion stake in drugmaker Pfizer. The hedge fund, headed by Jeff Smith, has become one of the most feared activist investors.

Meet Jeff Smith, the hedge-fund investor taking on Pfizer

Pfizer (PFE, Financial) stock saw a notable increase of 2.94% attributed to a reported $1 billion investment by activist investor Starboard Value. This strategic move is intended to breathe new life into Pfizer, as the stock has experienced a substantial decrease from its highs during the pandemic era.

Pfizer (PFE) Surges on Starboard's $1 Billion Investment Plan

Can Starboard Value and former CEO Ian Read save Pfizer stock?

Why Pfizer Stock Popped on Monday

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.

5 Large Drug Stocks to Watch From a Thriving Industry

Pfizer stock popped Monday on a report activist investor Starboard Value took a roughly $1 billion stake in the struggling drugmaker.

Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Media reports indicate that activist investor Starboard Value has acquired approximately $1 billion worth of shares in Pfizer (PFE, Financial). Following this news, Pfizer's stock rose nearly 3% in pre-market trading.

Starboard Value's $1 Billion Stake Boosts Pfizer (PFE) Shares

Pfizer Inc. NYSE: PFE hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE NASDAQ: BNTX sent shares surging up to $61.71 in December 2021, driven by its COVID-19 vaccine sales. Since then, it's been downhill for the medical sector giant as COVID revenues dried up with the pandemic in the rearview mirror.

4 Reasons Pfizer Could Be a Value Play You Can't Miss

Tesla

The futures market is showing a downward trend this morning. The S&P 500 futures are down 24 points, the Nasdaq 100 futures have fallen 110 points, and the Dow Jones Industrial Average futures have decreased by 161 points.

Morning Brew: GEICO Drops Tesla Cybertruck, Pfizer Gains Activist Investor

Pfizer Inc. PFE may have been a hero in the COVID-19 vaccine race, but its stock is stuck in the slow lane. Down nearly 14% over the last year, the pharma giant's shares have struggled as demand for its pandemic-related treatments has fizzled out.

Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?

Shares of Pfizer (PFE) are rising in premarket trading Monday following a report that activist investor Starboard Value has taken a roughly $1 billion stake in the struggling drugmaker.

Pfizer Stock Rises on Report Starboard Takes Roughly $1B Stake

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine.

Pfizer wins bid to invalidate GSK's patents over RSV vaccine

Activist investor Starboard Value has reportedly amassed a $1 billion stake in Pfizer.

Pfizer Has an Activist. Pharma Giant Is Latest Target of Starboard.

In a bid to reshape Pfizer's future, activist investor Starboard Value has acquired a stake worth approximately $1 billion, according to reports. The move comes as the pharmaceutical giant faces mounting challenges, including declining demand for its Covid-19 products and increased competition.

Starboard Value's $1 billion move: will Pfizer see a much-needed revival?

Activist investor Starboard Value has acquired a $1 billion stake in Pfizer Inc (NYSE:PFE, ETR:PFE) and is pushing for changes at the pharmaceutical giant, according to the Wall Street Journal. While Starboard's specific plans remain unclear, it has reportedly engaged with former Pfizer executives Ian Read and Frank D'Amelio to support its efforts.

Pfizer: Activist investor Starboard Value takes $1bn stake

Activist investor Starboard Value has taken a $1 billion stake in beleaguered drugmaker Pfizer Inc. and is seeking a turnaround, the Wall Street Journal reported late Sunday.

News for Pfizer Stock (PFE)